Covidien, a leading global provider of healthcare products, and PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. and a leader in radiopharmaceutical distribution, jointly announced they have entered into a co-marketing agreement to offer a combined portfolio of high energy and low energy radioisotopes to the nuclear medicine community in the United States.

Through the agreement, Covidien Imaging Solutions and PETNET will create a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radiopharmaceuticals, designed to illuminate conditions, such as cancer or heart disease, during imaging procedures. The agreement brings together Covidien's single photo emission computed tomography (SPECT) products and PETNET's positron emission tomography (PET) products.

«« Hologic Gets CE Mark for Celero Device


Toshiba and Maquet Partnership to Offer Hybrid Solutions for Infinix-i »»


Latest Articles

Covidien, a leading global provider of healthcare products, and PETNET Solutions, a wholly-owned subsidiary of Siemens Medical Solutions USA, Inc. and a...